I have been searching the cyber highway for a few hour's now in reading up
on Raloxifene/Evista vs. Tamoxifen. I was shocked when I read that with
breast cancer you have surgery, Radiation and then Tamoxifen. Why was I so
shocked? Well, my wonderful doctor did surgery, no radiation, then
tamoxifen ! Where's my lawyer????
It should be noted that the Tamoxifen works on one form of breast cancer;
which is the most common form ductural. Raloxifene works for both ductural
and invasive breast cancers. Tamoxifen has a lower rate of prevention than
Raloxifene, along with many more side effects of a serious nature.
Raloxifene also helps with colestorial. In many of the articles and reports
on Tamoxifen I would read "Tamoxifen MAY reduce the risk of breast cancer".
The last; but not least is that both drugs only work for a certain period of
time to our knowledge. I would question if you were on Tamoxifen for 5
year's, could you go on Raloxifene/Evista say for another three year's? Not
to appear greedy; but then life is worth being greedy about. I hope that I
have helped all of you in the decisions that face each of us with this
desease and pray that the time bought will find a cure for us. Lovingly
your friend, lillian
The Wall Street Journal -- December 11, 1998
In Cancer Test
By Thomas M. Burton
Staff Reporter of The Wall Street Journal
Clinical trials of the osteoporosis drug Evista show it is associated with a
55% reduction in the risk of
breast cancer after more than three years of use by women.
Zeneca Says Its Tamoxifen Drug Reduces Some Recurrence
of Breast Cancer
December 12, 1998, 7:45 a.m. PT
San Antonio, Texas, Dec. 12 (Bloomberg) -- Zeneca Group Plc,
the world's second-biggest maker of cancer drugs, said its
tamoxifen drug reduced the recurrence of breast cancer in women
who have cancerous cells removed and undergo radiation. (45% reduction with
Raloxifene (Evista): An Anti-Estrogen to Prevent Breast Cancer
Another anti-estrogen compound, Raloxifene (Evista), has also been found to
reduce the incidence of breast cancer. Importantly, it is possible that
Evista will do this without the disturbing side effect that Tamoxifen has of
increasing the incidence of uterine cancer. Raloxifene is a novel estrogen
receptor drug that has the estrogen–like effects of bone preserving and
lipid lowering (estrogens have these good effects naturally), but inhibits
the effects of estrogen on the breast and uterus. Remember, the normal
effect of estrogens on the breast and uterus are to make the cells grow.
That's why doctors and scientists think that inhibiting the effects of
estrogens on the breast may help prevent breast cancer. To read more about
this topic, read our Tamoxifen page. To be technically correct, Evista is
not really an "anti-estrogen", but is really in a new class of drugs called
SERMs (Selective Estrogen Receptor Modulators).
The Raloxifene Clinical Trial
The Multiple Outcomes of Raloxifene Evaluation (MORE) measured whether
cancer-free women (7,704 post-menopausal women under the age of 80) had a
lower risk of fracture, breast and endometrial cancer with the
administration of 3 years of Raloxifene (Evista). The drug significantly
reduced the risk of breast cancer, from 22 cases reported in the placebo arm
to 13 in the treatment arm. This finding represents a RR = 0.30, or a 70%
reduction in the risk of breast cancer. Endometrial cancer developed equally
in the treatment and placebo arms. In another study of 10,553 healthy women,
Raloxifene reduced the incidence of breast cancer 54% overall at a median
(average) follow-up of 33 months.
Osteoporosis Drug Evista® (Raloxifene) Cuts Newly Diagnosed, Invasive Breast
Cancer Risk By More Than 60 Percent
SAN ANTONIO --- New research findings show that the osteoporosis preventive
drug raloxifene (Evista®) reduces risk for newly diagnosed, invasive breast
cancer -- potentially the most serious type of the disease-- by more than 60
Noted breast cancer researcher V. Craig Jordan will discuss these findings,
which are the latest results from Eli Lilly and Company's ongoing studies of
raloxifene, at the 21st San Antonio Breast Cancer Symposium in San Antonio,
Tex., on Saturday, Dec. 12.
Jordan, a professor of cancer pharmacology at Northwestern University
Medical School, is also director of the Breast Cancer Research Program at
the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Raloxifene is the first osteoporosis preventive drug to show reduction in
the risk of breast cancer in clinical trials among women at average risk for
developing breast cancer.
Over 10,000 postmenopausal women age 31 to 80 taking raloxifene for more
than three years had a 63 percent reduction in the incidence of newly
diagnosed, invasive breast cancers when compared to their counterparts
taking placebo. These women also showed a 55 percent overall reduction in
both newly diagnosed invasive and non-invasive breast cancer.
These data were gathered from 10 randomized, double-blind,
placebo-controlled osteoporosis studies. The women were taking daily
raloxifene therapy for a follow-up of 40 to 55 months. Mammograms were
routinely performed on an annual or biannual basis in all placebo-controlled
trials of at least 12-months' duration.
The data are an update from those Jordan presented earlier this year at the
American Society of Clinical Oncology.
The cancer preventive potential of raloxifene will be further explored in
the upcoming Study of Tamoxifen and Raloxifene (STAR) trial, a landmark
breast cancer prevention trial comparing the ability of tamoxifen and
raloxifene to prevent breast cancer. The STAR trial will determine the
safety and effectiveness of raloxifene in reducing the occurrence of breast
cancer in women at high risk. Enrollment for the trial is expected to begin
Raloxifene is an antiestrogen, a drug that works by blocking the estrogen
receptors in the breast, thereby preventing the hormone estrogen from
contributing to the growth of cancer. Jordan and other breast cancer
researchers believe that the estrogenic properties of drugs such as
raloxifene prevent osteoporosis and may be target to prevent heart attacks
in postmenopausal women.
Raloxifene is the only selective estrogen receptor modulator (SERM)
available in the United States to protect postmenopausal women against the
rapid loss of bone that occurs after menopause and often leads to thinning
bones, osteoporosis and fractures. Besides its effects on the breast,
raloxifene has been shown to protect postmenopausal women against bone loss
and osteoporosis-related fractures and also lowers cholesterol.
Raloxifene is indicated for the prevention of postmenopausal osteoporosis in
the United States and is currently approved for marketing in 36 countries
worldwide, including the United States.
Raloxifene May Cut Breast Cancer Risk
April 22, 1998
NEW YORK (Reuters Health) -- Preliminary reports suggest that raloxifene, a
drug used to prevent osteoporosis in postmenopausal women, may also prevent
These reports come 2 weeks after researchers announced that tamoxifen, a
drug used in breast cancer patients, appeared to reduce the risk of breast
cancer in women at high risk by 45%. But tamoxifen carries risks of serious
side effects, including endometrial cancer. According to the reports on
raloxifene, it is as effective as tamoxifen in preventing breast cancer, but
has not been linked to an increased risk of endometrial cancer.
The data were supposed to be kept under wraps until the second week in May
when the full study is scheduled to be presented during the 34th annual
meeting of the American Society of Clinical Oncology (ASCO), due to be held
in Los Angeles, California. However, reports linking the drug to reduced
risk of breast cancer were published in The Wall Street Journal on Monday
and in the Tuesday edition of The New York Times.
Raloxifene, a selective estrogen receptor modulator (SERM), is marketed
under the name Evista. The drug's manufacturer, Eli Lilly and Company, is
telling the media that they will not comment on the studies until they are
officially presented at ASCO in May. "We cannot talk specifically about
these data due to ASCO's embargo limitations," according to a statement from
Angela Sekston, a spokesperson for Lilly told Reuters Tuesday, "We are
encouraged by the data we have to date (and) we look forward to presenting
the information in the appropriate forum at (ASCO)."
In the statement, Lilly revealed that nine studies involving over 10,000
postmenopausal women have shown that those taking the drug "had significant
reductions in the incidence of newly-diagnosed breast cancers."
"The ASCO presentations will provide scientific data to support the possible
role of Evista in preventing breast cancer among postmenopausal women. Proof
of this concept will await the development of more long-term data on
Evista," according to the press release from the Indianapolis-based
As reported by Reuters in March, a Lilly researcher has said that fewer
breast cancer cases have been noted in women taking raloxifene compared with
those taking placebo. Speaking at the American Cancer Society's Science
Writers Seminar in Newport Beach, Dr. Kapil Dhingra also discussed an
experimental drug called LY353381.HC1. In animal studies, this drug has been
shown to bind to estrogen receptors 10 times more strongly than raloxifene,
and appears to be even more effective in preventing cancer. More studies of
this drug are underway, but results on its role in preventing cancer may
take 5 to 10 years.
Lilly is also about to begin a large study to assess if Evista can prevent
heart attacks or heart-related deaths in postmenopausal women. The
Raloxifene Use for the Heart (RUTH) trial is set to begin enrolling 10,000
women worldwide in May and June.
Evista was approved in December 1997 for the prevention of osteoporosis in
postmenopausal women. It was the first drug in the SERM class to win
approval from the US Food and Drug Administration. According to a Lilly
statement issued at that time, Evista "is being studied for its selective
ability to act like estrogen in some tissues but not in others."
Copyright 1995-1998 Reuters Ltd. All rights reserved. Republication or
redistribution of Reuters content is expressly prohibited without the prior
written consent of Reuters. Reuters shall not be liable for any errors or
delays in the content, or for any actions taken in reliance thereon.
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email